These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37998738)

  • 41. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
    Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 44. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
    Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
    Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD21
    Nishimura K; Konishi T; Ochi T; Watanabe R; Noda T; Fukumoto T; Miura N; Miyauchi Y; Kikugawa T; Takenaka K; Saika T
    J Pers Med; 2022 May; 12(6):. PubMed ID: 35743673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events.
    Teimouri A; Minard LV; Scott SN; Daniels A; Snow S
    Curr Oncol; 2022 Apr; 29(5):3104-3117. PubMed ID: 35621642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
    De Velasco G; Je Y; Bossé D; Awad MM; Ott PA; Moreira RB; Schutz F; Bellmunt J; Sonpavde GP; Hodi FS; Choueiri TK
    Cancer Immunol Res; 2017 Apr; 5(4):312-318. PubMed ID: 28246107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    Kawahira M; Kanmura S; Mizuno K; Machida K; Ohtsuka T; Sato M; Enokida H; Yamashita M; Kanekura T; Arima S; Nakamura N; Sugiura T; Yoshimoto K; Kobayashi H; Ishitsuka K; Suzuki S; Ueno S; Ido A
    PLoS One; 2022; 17(4):e0267572. PubMed ID: 35482642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
    Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
    Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Isawa T; Toi Y; Sugawara S; Taguri M; Toyoda S
    Oncologist; 2022 May; 27(5):e410-e419. PubMed ID: 35348766
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.